adagrasib
mirati
['lcsm,(-blcsm)', 'lung', 'sclc', 'nsclc', 'adagrasib', 'medsir']
dr. al spira from shows data that adagrasib showed promising efficacy (orr 43%; dcr 80%; 1y os 51%) and a tolerable profile in advanced/metastatic nsclc harboring a krasg12c mutation.
#asco22 #lungcancer #lcsm 
Bring your idea to life?? 
Creating successful IITs & optimizing drug development ?? 
Medica Scientia Innovation Research
 ????&????
https://t.co/yp3O5Lylqc